EHA 2017 | Adoptive T-cell therapy for the treatment of MM
Ivan Borrello
• 22 Jun 2017
Ivan Marques Borrello, MD, from the John Hopkins School of Medicine, Baltimore, MD, USA, talks to us about the impressive results obtained from trials involving the combination of immune checkpoint inhibitors with IMiDs in treating multiple myeloma (MM). The idea of BCMA as a promising target for treating MM, along with the effectiveness and risks associated with the use of adoptive T-cell therapy via the use of CAR T-cells in treating MM is also discussed here. He concludes with a note on how his lab has designed an alternative approach through use of marrow-infiltrating lymphocytes, to minimise these risks. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
